Syros Pharmaceuticals Inc.

+0.03 (+3.90%)
Products, Regulatory

Syros Says First Patient Dosed In SELECT-AML-1 Trial Of Tamibarotene In Combination With Venetoclax And Azacitidine In Newly Diagnosed Unfit AML

Published: 09/09/2021 12:16 GMT
Syros Pharmaceuticals Inc. (SYRS) - Syros Announces First Patient Dosed in Select-aml-1 Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Newly Diagnosed Unfit Aml.
Syros Pharmaceuticals Inc - Initial Data From Phase 2 Trial Expected in 2022.
Syros Pharmaceuticals Inc - Evaluating Tamibarotene in Combination With Azacitidine in Select-mds-1 Phase 3 Clinical Trial.
Syros Pharmaceuticals - Evaluating Tamibarotene With Azacitidine in Rara-positive Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndrome.